Ribociclib, palbociclib, abemaciclib, and dalpiciclib in advanced breast cancer showed improved progression-free survival in patients with HR+/HER2- advanced breast cancer Christos Papadimitriou and overall survival [15,16,17,18]. The gene discussed is HR; the disease is breast carcinoma.